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Abstract
Objective—Animal and in vitro studies indicate that leptin alleviates starvation-induced
reduction in circulating vaspin and stimulates the production of visfatin. We thus examined
whether vaspin and visfatin are affected by short- and long-term energy deprivation and leptin
administration in human subjects in vivo.
Design and Methods—We measured circulating levels of vaspin and visfatin 1) before and
after 72-h of starvation (leading to severe hypoleptinemia) with or without leptin administration in
replacement doses in 13 normal-weight subjects, 2) before and after 72-h of starvation with leptin
administration in pharmacological doses in 13 lean and obese subjects, 3) during chronic energy
deficiency in 8 women with hypothalamic amenorrhea on leptin replacement for 3 months, and 4)
during chronic energy deficiency in 18 women with hypothalamic amenorrhea on leptin
replacement or placebo for 3 months.
Results—Acute starvation decreased serum leptin (to 21% of baseline values, P=0.002) but had
no significant effect on vaspin and visfatin concentrations (P>0.05). Nor did normalization of
leptin levels affect the concentrations of these two adipokines (P>0.9). Leptin replacement in
women with hypothalamic amenorrhea did not significantly alter vaspin and visfatin
concentrations, whether relative to baseline (P>0.15) or relative to placebo administration (P>0.9).
Pharmacological doses of leptin did not affect circulating vaspin and visfatin concentrations
(P>0.9).
Conclusions—Circulating vaspin and visfatin are not affected by acute or chronic energy
deficiency leading to hypoleptinemia and are not regulated by leptin in human subjects, indicating
that these adipocyte-secreted hormonal regulators of metabolism are independently regulated in
humans.
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INTRODUCTION
Adipose tissue has been increasingly recognized as an important endocrine organ.
Approximately 30 biologically active peptides and proteins (adipokines) are produced and
secreted by adipose tissue and play key roles in the regulation of food intake and energy
balance, insulin action, and glucose and lipid metabolism (1, 2). Vaspin (visceral adipose
tissue-derived serine protease inhibitor) and visfatin (pre-B-cell colony-enhancing factor,
PBEF) are two relatively new and less well described peptides secreted from white adipose
tissue. Studies in animal models indicate that vaspin is an endogenous insulin sensitizer (3)
and that visfatin has insulin-mimetic effects (4). Both adipokines are elevated in overweight
and obese type 2 diabetic patients (5). Dysregulation of adipose tissue secretory function,
such as that occurring in obesity (excess body fat) (6), has been linked with an array of
metabolic complications. The lack of normal adipose tissue, e.g. in lipodystrophy and
lipoatrophy, is also associated with dysmetabolic sequelae similar to what is seen in obesity
(7). Hypoleptinemia is prevalent in energy deprivation states in humans, such as food
deprivation/starvation, lipoatrophy, and exercise induced hypothalamic amenorrhea, and
exogenous metreleptin administration corrects many of the metabolic and neuroendocrine
abnormalities characteristic of these conditions (8–12).
It remains unknown whether these adipocyte-secreted hormones are acting independently
from each other or whether secretion or administration of one influences the other. In rats,
fasting decreases serum vaspin levels which are partly normalized by exogenous leptin
administration (13). Leptin in physiological doses has also been reported to stimulate the
production and secretion of visfatin from murine and human omental adipose tissue ex vivo
and in mouse 3T3-L1 adipocytes in vitro (14) but animal and in vitro data cannot be directly
translated into human biology. There is currently no information on whether leptin, which
decreases in energy deprivation states, mediates changes in circulating vaspin and visfatin in
humans in vivo. Furthermore, nothing is known regarding the in vivo regulation of vaspin
and visfatin levels in humans by energy deficit per se, whether acute or chronic. Thus, in this
study we first assessed circulating vaspin and visfatin in healthy men and women in
response to acute energy deficit with and without leptin administration in physiological
replacement and pharmacological doses which would alleviate the significant
hypoleptinemia induced by acute energy deficit. We then assessed circulating vaspin and
visfatin in women with exercise-induced chronic energy deficit and resultant
hypoleptinemia, with or without exogenous leptin given at replacement doses.
MATERIALS AND METHODS
The study protocols were approved by the institutional review board of the Beth Israel
Deaconess Medical Center (BIDMC) and recombinant methionyl human leptin (metreleptin;
formerly r-metHuLeptin) was administered under an FDA-approved, investigator-initiated
IND. The same clinical quality leptin was supplied initially by Amgen, Inc. (Thousand
Oaks, CA) and later on by Amylin Pharmaceuticals, Inc. (San Diego, CA). Administration
regimes were chosen on the basis of leptin pharmacokinetics (15–17) and modified as per
protocol demands. All subjects were informed about the risks associated with the study
procedures and gave their written informed consent.
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Study 1: Short-term energy deprivation (clinical trial registration: n/a)
Six men (age 23.5±1.5 years) and seven women (age 23.7±1.5 years) with a body mass
index (BMI) < 25 kg/m2 were studied during three separate admissions in the BIDMC
General Clinical Research Center (GCRC). These studies were carried out between 2002
and 2006 and were designed to evaluate the role of leptin in the neuroendocrine and immune
response to fasting (18, 19). Each subject completed three 3-day trials in random order: a 72-
h control trial (fed state), a 72-h total fasting with administration of placebo, and a 72-h total
fasting with administration of replacement doses of metreleptin. Briefly, for each trial,
subjects were admitted to the GCRC the night before starting the study. Blood samples were
obtained at 0800 h on day 1 and at 0800 h on day 3 for measurement of leptin, vaspin, and
visfatin concentrations. Each admission was separated by at least 7 weeks to permit recovery
of leptin levels and weight to baseline. Metreleptin was administered at a dose of 0.04 (men)
or 0.08 (women) mg/kg/day on the first day and 0.1 (men) or 0.2 (women) mg/kg/day on the
second and third days, to account for the progressive decrease in leptin concentration with
additional days of fasting (on the basis of our pharmacokinetic studies) (15–17). The total
daily metreleptin dose for each 24-h period was divided into four equal doses given every 6
hours by subcutaneous injection (administered by nursing staff) to mimic the normal diurnal
variation in leptin levels (17). Placebo was administered according to the same schedule as
metreleptin.
Study 2: High-dose leptin treatment (clinical trial registration: clinicaltrials.gov,
NCT00140205)
The effect of high-dose leptin treatment on vaspin and visfatin were evaluated as part of a
pharmacokinetic study of metreleptin carried our between 2006 and 2008 (15). Five healthy
men (age: 22.2±0.9 years) and five healthy women (age: 20.4±0.7 years) with a BMI <25
kg/m2, and five obese but otherwise healthy men (age: 23.4±1.5 years) with a BMI >30 kg/
m2, were admitted to the GCRC at the BIDMC for a 3-day fasting study with subcutaneous
administration of metreleptin at a pharmacological dose of 0.3 mg/kg, once daily at 0800 h
for 3 consecutive days. Blood samples were obtained at 0800 h on days 1 and 3 for
measurement of leptin, vaspin, and visfatin concentrations. Details of this protocol have
been described previously (15).
Study 3: Chronic energy deprivation - open label (clinical trial registration: n/a)
Eight women (age 24.8±1.9 years) with relative hypoleptinemia (<5 ng/ml) and
hypothalamic amenorrhea for at least six months due to strenuous exercise or low weight
were enrolled, and were studied before and after treatment with metreleptin for 3 months.
The study was carried out between 2002 and 2004; the clinical characteristics and methods
have been previously described in detail (9). Subjects self-administered metreleptin (0.08
mg/kg/day) subcutaneously for 3 months, with 40% of the daily dose given at 0800 h and
60% at 2000 h to mimic the normal diurnal variation in leptin concentrations (17). They
were instructed not to change their diet and exercise habits for the duration of the study.
Blood samples were obtained monthly for the measurement of leptin, vaspin and visfatin
concentrations.
Study 4: Chronic energy deprivation - double blinded (clinical trial registration:
clinicaltrials.gov, NCT00130117)
Eighteen women (age 25.0±2.2 years) with hypothalamic amenorrhea for at least six months
and relative hypoleptinemia (<5 ng/ml) due to strenuous exercise or low weight were
evaluated as part of a larger study on the effects of metreleptin on neuroendocrine function,
carried out between 2008 and 2010 (20). Patient characteristics and detailed methods have
been described elsewhere (20). The participants were randomized in a 1:1 ratio to receive
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either metreleptin or placebo. Metreleptin (0.08 mg/kg/day) or matching placebo doses were
self-administered by subcutaneous injection daily between 1900 h and 2300 h for 3 months.
According to our previous studies (15–17), the dose of metreleptin was calculated based on
each subject’s weight to achieve physiologic leptin concentrations in blood, but given as a
single injection to facilitate compliance. Blood samples for the measurement of leptin,
vaspin, and visfatin concentrations were obtained at baseline and after 3 months of
treatment.
Hormone measurements
All samples used were stored at −80°C until assayed. Leptin concentration was measured by
radioimmunoassay (Millipore, Billerica, MA) with a sensitivity of 0.5 ng/ml. Vaspin
concentration was measured by using a commercially available ELISA kit (ALPCO
Diagnostics, Salem, NH) with a sensitivity of 12 pg/ml. Visfatin concentration was
measured by using a commercially available EIA kit (ALPCO Diagnostics, Salem, NH) with
a sensitivity of 30 pg/ml. All samples were run in duplicate with quality controls, and inter-
and intra-assay coefficients of variation for all analytes were <15%. In routine evaluation in
our laboratory, as well as previously published data (21–24), suggest that long-term storage
and freezing/thawing does not affect levels of the molecules of interest.
Statistical analysis
The results are presented as mean ± SEM. Statistical analyses were performed by using
SPSS 11.0 (SPSS, Chicago, IL), and a two-tailed P <0.05 was considered statistically
significant. For study 1 (short-term energy deficit), paired t tests were used to assess changes
in hormone levels within each condition. To determine whether these changes varied
between conditions, we used a mixed-effects model repeated-measure ANOVA. For study 2
(high-dose leptin treatment), paired t tests were used to assess changes in hormone levels.
For study 3 and study 4 (the two chronic energy deficit studies), changes in hormone levels
were analyzed by using a mixed-effects model repeated-measures ANOVA and mixed
model analysis. For comparing changes between the metreleptin- and placebo-treated
groups, we used repeated measures analysis as primary analysis to evaluate changes in
hormone levels by overall P-values for the main effect of treatment and treatment by time
interaction. One-way ANOVA followed by the protected least significant-differences
technique was used to compare differences between the two treatment groups for baseline
characteristics and for follow-up measurements. Statistical analyses were conducted using
on-treatment analysis.
RESULTS
Study 1: Short-term energy deprivation
Leptin concentration was significantly reduced after 3 days of fasting (from 8.5 ± 2.3 ng/ml
to 1.8 ± 0.4 ng/ml, P = 0.002) and metreleptin administration reversed this change (both P =
0.002); vaspin and visfatin concentrations were not affected by short-term fasting nor leptin
replacement (Table 1).
Study 2: High-dose leptin treatment
Pharmacological doses of leptin during 3 days of fasting had no significant effects on serum
vaspin (0.68 ± 0.05 vs. 0.68 ± 0.05 ng/ml on days 1 and 3, respectively; P = 0.981) and
visfatin (4.36 ± 0.29 vs. 4.31 ± 0.35 ng/ml on days 1 and 3, respectively; P = 0.907)
concentrations.
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Study 3: Chronic energy deprivation - open label leptin treatment
Open-label metreleptin treatment for 3 months in women with hypothalamic amenorrhea
significantly decreased body weight (54.7±4.5 kg to 52.2±3.5 kg; P <0.001) and increased
serum leptin concentrations to physiologic levels during the first 2 months and to mildly
supraphysiologic levels during the third month at the higher dose (Table 2). There were no
significant changes in circulating vaspin or visfatin (Table 2).
Study 4: Chronic energy deprivation - double blind, placebo controlled, randomized leptin
treatment
In the double blind, placebo controlled, randomized study, metreleptin treatment decreased
body weight only slightly but significantly (55.6±2.0 kg to 55.5±1.7 kg; P = 0.046) whereas
no change was observed with placebo administration (55.4±2.3 kg to 56.9±1.8; P =0.727).
Despite the significant increase in serum leptin concentration, there were no significant
changes in circulating vaspin or visfatin (Table 3).
DISCUSSION
We found that neither short-term energy deprivation (72 hours of total fasting) nor chronic
energy deficit (hypothalamic amenorrhea) affect serum concentrations of vaspin and
visfatin. Since energy deprivation states are typically associated with hypoleptinemia, we
also studied whether metreleptin administration in either replacement doses to normalize
circulating leptin levels or pharmacological doses that would increase serum leptin levels at
or beyond the physiological range would alter the concentrations of these two adipokines.
We observed that metreleptin has no significant effect on circulating vaspin and visfatin
levels. We thus conclude that: 1) vaspin and visfatin are not likely involved in the
development of metabolic and neuroendocrine changes which are typical in states of energy
deficiency in humans, and 2) leptin does not modulate the levels of these two adipokines.
Leptin is a pleiotropic hormone; in addition to regulating energy homeostasis, it has
important roles in neuroendocrine, reproductive and immune functions (8, 25, 26). Leptin
conveys information to the central nervous system (CNS) regarding energy availability in
the body, a system that is particularly sensitive to energy deprivation. In both humans and
animals, states of acute and chronic energy deprivation are characterized by hypoleptinemia
and metabolic and neuroendocrine dysfunction, which are normalized with the
administration of leptin (9, 27, 28). Leptin exerts its actions by binding to its receptors in
both the CNS and the periphery and activating signal transduction pathways that overlap
with but are distinct from insulin signaling pathways (29). As vaspin and visfatin are novel
adipokines exhibiting insulin sensitizing and/or mimetic effects (3, 4), we examined whether
leptin regulates the circulating levels of these adipokines by conducting interventional
studies in humans involving acute and chronic energy deficiency and leptin administration.
Vaspin is a recently discovered adipocytokine (3). The administration of recombinant vaspin
in mice was shown to improve glucose tolerance and insulin sensitivity, identifying this
novel adipokine as an insulin sensitizer (3). However, recent cross-sectional studies in
humans do not confirm the association between circulating vaspin and glucose tolerance
status or insulin sensitivity measured with the hyperinsulinemic clamp technique (30). Still,
serum vaspin concentrations are elevated in obesity and type 2 diabetes, and this adipokine
has thus been suggested to serve as a biomarker of obesity-related impairment in insulin
sensitivity (5, 31, 32). Recent studies in humans have shown significant and direct
associations between leptin and vaspin concentrations (23, 33). Also, a study in rats
observed that fasting for 24 h or 48 h decreases circulating vaspin and this effect is partly
abolished by exogenous leptin administration (13). Contrary to these findings, a recent
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observational study in a small number of human subjects reported a preprandial rise and
postprandial fall in vaspin levels (34) indicating that either feeding or feeding-related factors
such as insulin, which also regulates leptin levels (35) and/or leptin may be reciprocally
related to these daily changes in vaspin levels. To test and expand the hypothesis raised by
the above observational study in a systematic and methodical manner, we performed
interventional studies involving short- and long-term energy deficit with or without leptin
replacement in physiologic and pharmacologic doses. We found that neither total fasting for
72 h nor leptin administration in replacement or pharmacologic doses significantly affected
vaspin concentrations in healthy lean and obese men and women. Likewise, we observed no
effect of chronic energy deficiency per se or leptin replacement in a condition of chronic
energy deficit (hypothalamic amenorrhea). The inconsistency of the results between animals
and humans could be related to differences in the relative contribution of visceral fat
(secreting vaspin) to total body fat. Alternatively, it is also possible that the cellular
regulation of vaspin production and secretion in rodents is not similar to that in humans. The
fact we did not detect any changes in vaspin levels over a few days of fasting and/or in
response to leptin replacement may indicate that only short term signals of food intake such
as insulin may have an effect in altering vaspin levels in the short term, as previously
suggested (34).
Visfatin was originally identified as an adipokine exhibiting insulin-mimetic effects via
binding to and activating the insulin receptor (4). The results of observational studies on the
association between circulating visfatin concentrations and obesity and insulin resistance are
conflicting (4, 5, 36–40). In an observational study of obese human subjects, plasma visfatin
levels increased following intestinal bypass surgery, and post-surgery visfatin levels were
significantly correlated with post-surgery leptin levels and change in leptin levels following
surgery (41). Additionally, in vitro and ex vivo studies have shown that leptin increases
visfatin production in 3T3-L1 adipocytes and adipose tissue extracts from humans and mice
(14). In our short-term interventional studies, however, we found no effect of energy deficit
on circulating visfatin levels with or without exogenous metreleptin in replacement or
pharmacologic doses. In our model of chronic energy deprivation (exercise induced energy
deficiency and hypothalamic amenorrhea), visfatin levels also remained unchanged, even
with the normalization of leptin levels through administration of metreleptin for up to 3
months. These results are consistent with the absence of a significant change in circulating
visfatin following a long-term, calorie-restricted diet in women (42), as well as the absence
of a significant difference in serum visfatin levels between untreated patients with anorexia
nervosa and bulimia nervosa and healthy control subjects (43).
Although our studies were performed in relatively small sample sizes and thus the
possibility of a type II error cannot be fully excluded, a recently published study that
demonstrated effects of short term caloric intake and/or food deprivation on vaspin levels
was even smaller (34). Moreover, the various approaches taken, the convergence of similar
results from several independent studies and especially the randomized, double-blinded,
placebo-controlled design of both the short term and the chronic energy deprivation studies
add to the robustness of our results. In addition, we assessed circulating vaspin and visfatin
in models of both acute and chronic energy deficit and hypoleptinemia, with administration
of physiologic and pharmacologic doses of metreleptin. The range of leptin concentrations
achieved and the breadth of our analysis of these hormones strengthens the validity of our
results. Leptin, visfatin and vaspin were measured using established, state of the art
methodology with low laboratory error by technicians that were blinded to the study
hypothesis. However, in this study, we only assessed a potential effect of leptin but have not
studied any potential effects of insulin, as previously suggested (34). This remains to be
tested in the future.
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In summary, we have shown that 1) short- and long-term energy deficit in humans does not
affect circulating vaspin and visfatin, indicating that these adipokines are likely not involved
in the metabolic and neuroendocrine abnormalities characteristic of energy deprivation
states, and 2) leptin administration to alleviate hypoleptinemia does not significantly alter
vaspin or visfatin levels. Thus, our results argue against the existence of a cross-talk
between these adipokines and leptin which is not only of physiological significance but also
may have implications on whether these hormones could be administered and/or co-
administered, if and when they find their way in our therapeutic armamentarium.
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